MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology Officer of the company.  Dr. Stoica will lead the company’s global technology and product development operations, reporting to Joseph H. Capper, President and Chief Executive Officer. “We are delighted to welcome Andrei to our BioTelemetry team during this transformational time of growth and innovation,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry.  “His extensive expertise in enterprise technology solutions, including cloud platforms, information security, and software and product development, will be instrumental as we continue to create

Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval MALVERN, Pa., March 25, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced the activation of an expanded service using its Mobile Cardiac Outpatient Telemetry (MCOT™) to monitor life-threatening QT prolongation in COVID-19 patients. As a reminder, MCOT is the most accurate and studied arrhythmia monitoring detection system in the market. It provides up to 30 days of near real time monitoring without patients needing to leave their homes. The Company is currently implementing this COVID-19 monitoring initiative in several major institutions and

Announces Record Quarterly and Full Year Results MALVERN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter and year ended December 31, 2019. Quarter Highlights Recognized quarterly revenue of $112.0 million Reached 8.1% year-over-year quarterly revenue growth Achieved 30th consecutive quarter of year-over-year revenue growth Reported GAAP net income of $1.6 million, or 1.4% of revenue Realized quarterly adjusted EBITDA of $31.7 million, or 28.3% of revenue Received coverage from five new Blue Cross companies for MCT services President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “Our fourth

MALVERN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2019 earnings on Wednesday, February 26 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, February 26, 2020. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original

Exceeds Expectations Delivers Double Digit Revenue Growth MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2019. Quarter Highlights Recognized quarterly revenue of $111.3 million Reached 11.3% year-over-year revenue growth Achieved 29th consecutive quarter of year-over-year revenue growth Reported GAAP net income of $8.3 million Realized quarterly adjusted EBITDA of $31.5 million, or 28.3% of revenue President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “The third quarter was another excellent quarter for BioTelemetry, highlighted by 11% revenue growth and an adjusted EBITDA

MALVERN, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2019 earnings on Tuesday, November 5 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, November 5, 2019. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original

MALVERN, Pa., Aug. 05, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc.(NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Manish Wadhwa, M.D., F.H.R.S. (Fellow of the Heart Rhythm Society), has been named Chief Medical Officer. Dr. Wadhwa will lead the company’s clinical strategy and operations, reporting to Joseph H. Capper, President and Chief Executive Officer. Dr. Wadhwa, co-founder of Geneva Health Solutions, joined BioTelemetry in March 2019 as part of the company’s acquisition of Geneva. He is an actively practicing, board-certified cardiologist and cardiac electrophysiologist, serving the San Diego community in private practice since 2000. Dr. Wadhwa brings over 26 years of clinical experience with expertise in both

Exceeds Expectations Achieves Record Revenue and Adjusted EBITDA MALVERN, Pa., July 30, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc.(NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2019. Quarter Highlights Recognized record quarterly revenue of $111.8 million Reached 10.3% year-over-year revenue growth Achieved 28th consecutive quarter of year-over-year revenue growth Reported GAAP net income of $8.3 million Realized quarterly adjusted EBITDA of $31.6 million, or 28.3% of revenue Acquired Sweden-based ADEA Medical AB President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “Our growth momentum continued in the second quarter, with revenue growth of

MALVERN, Pa., July 24, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner. Through its BioTel Heart division, BioTelemetry processes over